A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer

NCT06158919 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer/Adenocarcinoma of Esophagogastric Junction

Interventions

DRUG: Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine

Sponsor

Fudan University